Please use this identifier to cite or link to this item:
Title: Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.
Authors: Alexandroff, AB
Nicholson, S
Patel, PM
Jackson, AM
First Published: Jul-2010
Citation: IMMUNOTHERAPY, 2010, 2 (4), pp. 551-560
Abstract: The concept of using Mycobacterium for cancer treatment goes back to the 19th Century. Today, bacillus Calmette-Guerin (BCG) vaccine is a well-established treatment for human bladder cancer that is arguably superior to intravesical chemotherapy for superficial disease and is commonly used as the first-line adjuvant treatment. Much has been learnt about the effects of BCG on bladder cancer and the immune system, but deeper understanding is required in order to improve its efficacy further, to be able to reliably predict responders and ultimately to adapt this most successful form of cancer immunotherapy for the treatment of other malignancies. This article summarizes the current understanding of BCG cancer immunotherapy mechanisms and discusses possible future developments.
DOI Link: 10.2217/imt.10.32
eISSN: 1750-7448
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.